 "Alembic Pharmaceuticals ups its US game plan, acquires Orit")
Alembic Pharmaceutical Ltd. (APL) posted a net profit of Rs 35 crore for the quarter ending March 31, 2022 after charging off non-recurring expenses of Rs. 188 crore, gaining from growth in its India and US businesses.
The company's India branded business was up by 25 per cent year-on-year (YoY) in Q4 of FY'22 at Rs 449 crore, up from Rs 358 crore in Q4 of previous fiscal year. APL's US generics business also grew by 17 per cent to Rs 557 crore in Q4 of FY'22 as against Rs 475 crore in Q4 of FY'21.
During the quarter, Alembic Pharma's US
